|
|
|
|
 |
 |
GlaxoSmithKline Press Releases |
 |
|
|
|
|
27th December, 2006
Landmark Tykerb® (lapatinib) data published in the New England Journal of Medicine
Landmark Tykerb® (lapatinib) data published in the New England Journal of Medicine
EMBARGOED UNTIL 5:00 pm ETUS/22:00 London, UK, December 27, 2006
Study Authors Also Conclude that Further Investigation Into Earlier Use In The Treatment of HER2 Positive Breast Cancer is Warranted
Data from a Phase III study reporting that Tykerb® (lapatinib) plus Xeloda® (capecitabine) is superior to capecitabine alone in women with HER2 (ErbB2) positive advanced breast cancer who had progressed following prior therapy, including Herceptin® (trastuzumab), was published today in the New England Journal of Medicine (NEJM).[1] Based on the findings, the study authors concluded that given its distinct mechanism of action and activity, as a small molecule dual receptor tyrosine kinase inhibitor, lapatinib should be investigated for use in the earlier treatment of HER2 (ErbB2) positive breast cancer.1 Lapatinib is an investigational medicinal product and has not been approved for marketing by any regulatory body ...
|
22nd December, 2006
GSK receives approvable letter for topical antibiotic, Altabax (retapamulin ointment), 1%
GSK receives approvable letter for topical antibiotic, Altabax (retapamulin ointment), 1%
Philadelphia, PA - December 22, 2006 -- GlaxoSmithKline (GSK) announced today that the U.S. Food and Drug Administration has issued an approvable letter for its topical antibacterial, Altabax (retapamulin ointment), 1%, for the treatment of secondarily-infected traumatic lesions (SITL) ...
|
21st December, 2006
GlaxoSmithKline to acquire Praecis Pharmaceuticals
GlaxoSmithKline to acquire Praecis Pharmaceuticals
GlaxoSmithKline plc (GSK) and Praecis Pharmaceuticals Incorporated (Nasdaq: PRCS) announced today execution of a definitive agreement providing for GSK to acquire all outstanding shares of Praecis’ common stock for a cash purchase price of US $5.00 per share or a total of approximately $54.8 million for the entire equity interest of Praecis ...
|
19th December, 2006
GlaxoSmithKline and Genmab enter global agreement for HuMax-CD20
GlaxoSmithKline and Genmab enter global agreement for HuMax-CD20
GlaxoSmithKline and Genmab announce exclusive worldwide agreement for the development and commercialization of HuMax-CD20 (ofatumumab)
Issued – Tuesday 19 December 2006, London, UK, USA and Copenhagen, Denmark - GlaxoSmithKline (GSK) and Genmab A/S (CSE:GEN) today announced a worldwide agreement to co-develop and commercialize HuMax-CD20™ (ofatumumab), a fully human monoclonal antibody in late stage development for CD20 positive B-cell chronic lymphocytic leukemia (B-CLL) and follicular non-Hodgkin’s lymphoma (NHL) and in Phase II for rheumatoid arthritis (RA) ...
|
19th December, 2006
Adrian Rawcliffe to lead GlaxoSmithKline’s Worldwide Business Development
Adrian Rawcliffe to lead GlaxoSmithKline’s Worldwide Business Development
Issued – Tuesday December 19 2006, London - GlaxoSmithKline (GSK) announces that Adrian Rawcliffe has been appointed Senior Vice President, Worldwide Business Development, Research & Development, effective immediately ...
|
19th December, 2006
GlaxoSmithKline completes acquisition of CNS, Inc.
GlaxoSmithKline completes acquisition of CNS, Inc.
GSK adds innovative, high-growth Breathe Right and
FiberChoice brands to Consumer Healthcare portfolio
Philadelphia, 19 December, 2006 - GlaxoSmithKline [LSE:GSK]
[NYSE:GSK] today announced that it has completed the acquisition of CNS, Inc ...
|
18th December, 2006
GlaxoSmithKline discontinues clinical development of investigational protease inhibitor brecanavir (640385)
GlaxoSmithKline discontinues clinical development of investigational protease inhibitor brecanavir (640385)
Issued — Monday 18 December 2006, London and Philadelphia
GlaxoSmithKline plc (GSK) today confirms that, due to insurmountable issues regarding formulation, development of brecanavir, an investigational protease inhibitor for the treatment of HIV, has been discontinued ...
|
15th December, 2006
GlaxoSmithKline reaches EU regulatory milestone in its flu pandemic vaccine development programme
GlaxoSmithKline reaches EU regulatory milestone in its flu pandemic vaccine development programme
Issued – Friday 15 December 2006, London, UK & Rixensart, Belgium -GlaxoSmithKline Biologicals today announced that Daronrix®, its first generation alum-adjuvanted inactivated whole virus candidate flu vaccine* for use once a pandemic has officially been declared by the WHO/EU, has received a positive opinion from Europe’s Committee for Medicinal Products for Human Use (CHMP) ...
|
13th December, 2006
Lapatinib (Tykerb®) to be evaluated in early stage disease in adjuvant breast cancer settings internationally
Lapatinib (Tykerb®) to be evaluated in early stage disease in adjuvant breast cancer settings internationally
First global trial investigates lapatinib in adjuvant settings to assess impact in early stage disease
Issued – Wednesday 13 December 2006, London, UK - Massachusetts General Hospital Cancer Center and GlaxoSmithKline (GSK), today announced the initiation of a landmark international breast cancer clinical trial, TEACH (Tykerb®Evaluation After CHemotherapy) ...
|
12th December, 2006
GlaxoSmithKline and EPIX Pharmaceuticals enter drug discovery and development alliance
GlaxoSmithKline and EPIX Pharmaceuticals enter drug discovery and development alliance
Issued — Tuesday 12 December 2006, London, UK & Lexington, MA
Collaboration includes discovery and development of four GPCR programmes
GlaxoSmithKline (GSK) and EPIX Pharmaceuticals today announced a worldwide multi-target strategic collaboration to discover, develop and market novel medicines targeting four G-protein coupled receptors (GPCRs) for the treatment of a variety of diseases, including EPIX’s novel 5-HT4 partial agonist programme, PRX-03140, in early-stage clinical development for the treatment of Alzheimer’s disease ...
|
|
|
|
Next 10 » |
|
|
|
|
